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Currently, 382 million people, or up to
8.8% of total world population, live with
diabetes mellitus (International Diabetes
Federation, 2013). By 2035, these num-
bers will reach 592 million acquiring the
characteristics of an epidemic, similar to
other lifestyle-related epidemics including
obesity, cardiovascular diseases and others.
Approximately 80% people with diabetes
live in low income countries. Specially
alarming is the spread of type 2 dia-
betes (T2D) among children including the
younger age group.
Annually, nearly 1 million people
undergo high lower extremity amputa-
tions because of complications of diabetes.
In other words, 1 amputation is being per-
formed worldwide every 20–30 s, and the
vast majority of these amputations are in
patients suffering from diabetic foot ulcers
(International Diabetes Federation, 2013).
Classically, the development of diabetic
foot ulcer is promoted by the diabetic
polyneuropathy and frequent traumati-
zation of the insensitive foot with fur-
ther bacterial or fungal contamination of
the wound, peripheral arterial occlusive
disease, and aggressive artheriosclerosis
observed commonly during persistent and
poorly controlled hyperglycemia (Vlassara
and Striker, 2013). The diabetic foot ulcers
themselves are regarded as precursors of
typically painless cardiovascular or cere-
brovascular major accidents, thus their
effective therapy mandates a multidisci-
plinary team approach.
Another major threat of lower limb
loss is the complexity of foot deformi-
ties in the already autosympathectomized
osteoarthropatic diabetic foot with habit-
ually intact arterial inflow. Subluxations,
fractures, swelling, and inflammation of
soft tissues in combination with reduced
sensitivity and loss of pain perception may
lead to disruption of skin integrity and
development of local infectious and gener-
alized septic complications. The degree of
damage in diabetic foot is directly related
to the socio-economic status and quality
of diabetic foot care. A quarter of diabetic
foot ulcers eventually result in minor or
major amputations of the affected limb.
Cases with lack of multifaceted treatment
and resultant higher level amputations
compose the high risk group for periop-
erative mortality and contralateral lower
limb loss within 3 years. The 5-year risk
of death in this group of patients surpasses
cancer mortality (International Diabetes
Federation, 2013).
The hyperglycemia is considered a clue
factor for tissue damage in diabetes (Nandi
and Poretsky, 2013). Multiple mechanisms
for diabetes development have been pro-
posed. However, the principal factor deter-
mining the disease progression is severity
and duration of hyperglycemia which, if
sustained, causes retinopathy, neuropathy,
ischemia, supports local infections, and
other complications of advanced diabetes.
Pathophysiological mechanisms predis-
posing to formation of tissue alteration
include generation of advanced glyca-
tion end-products (AGEs) or glycotox-
ins and action of advanced lipoxidation
products (ALEs) either of dietary ori-
gin or from intracellular sources (Gabbay
et al., 2014). As potent prooxidants,
they increase the intracellular oxidative
stress, deplete the anti-oxidant reserve,
and induce an inflammatory reaction. In
addition, AGEs appear to be directly cyto-
toxic to the pancreatic beta-cells. Besides
undergoing direct reduction in lysosomes,
AGEs undergo filtration in kidneys, which
makes these patients extremely vulnera-
ble to kidney dysfunction. Impaired renal
function markedly increases the over-
all oxidative stress in the whole organ-
ism including the vital organs. All these
detrimental effects significantly impact the
course of diabetic foot.
The perioperative period in these
patients is characterized by superimposi-
tion of procedure-related additional risks
and adverse factors on the already exist-
ing hyperglycemia, infection and tissue
alteration. Perioperative management of
patients undergoing procedures to treat
the diabetic foot requires preoperative sta-
bilization of the vital organs, infection
control, restoring of the acid-base balance,
correction of electrolytes, colloid-osmotic
pressure, and blood volume. It is crucial
to tightly control the blood glucose level.
Many times, intraoperative insulin infu-
sion under control of blood glucose level
is justified to prevent hyperglycemia and
improve the outcome.
Reduced antioxidant defenses can be
restored by restriction of dietary AGEs
and ALEs (e.g. red meat) and prescrip-
tion of drugs with antioxidant proper-
ties (Kang et al., 1998; Corathers et al.,
2013; Kim and Steinberg, 2013). Gabbay
et al. (2014) hypothesize that the tissue
blood flow in diabetic foot is rerouted
through the metarteriole thoroughfare
channel, bypassing the exchange capillar-
ies (Gabbay et al., 2014). This disables the
nutrient and oxygen exchange in tissues
and results in local hypoxia.
Diabetic patients typically suffer from
symmetric bilateral tibial stenoses with rel-
atively spared femoral and pedal arteries.
The development of macrovascular dis-
orders suggests symptomatic peripheral
arterial disease and possibility of effec-
tive restoration of the arterial inflow in
the large vessels (Jindal et al., 2013).
However, successful resumption of blood
flow in major vessels does not necessar-
ily correlate with adequate perfusion of
the tissues because of altered capillary
circulation and neuropathic vascular tone
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dysregulation (Zambouri, 2007; Šponer
et al., 2013). In these cases the blood rheol-
ogy improvement turns especially impor-
tant. Controlled anticoagulation is highly
recommended with perioperative INR 1,5
achievement, which is considered to be
generally safe for intra-postoperative inva-
sive surgical major hemorrhagic complica-
tions, meantime significantly improves the
perfusion of myocardium, brain, kidneys,
extremities (Zambouri, 2007; Jindal et al.,
2013).
The administration of intravenous
(IV) heparin or subcutaneous (SC)
low-molecular-weight heparin (LMWH)
should be individualized. It takes approxi-
mately 3 days for the INR to reach 2.0 once
oral anticoagulant is restarted postopera-
tively (Frykberg et al., 2006; Zambouri,
2007).
Frequently, therapy of the related
comorbidities including the underlying
chronic or acute disseminated intravascu-
lar coagulation allows for more significant
improvement of microcirculation than
poorly justified aggressive invasive vas-
cular interventions (O’Reilly et al.,
2011).
Further assessment and treatment of
concomitant acute regional septic arteriitis
and phlebitis is paramount, as infection
control will help to reverse the microcircu-
latory impairment (Corathers et al., 2013).
Severe diabetic neuropathy is the
principal contributor to development
of neuropathic osteoarthropathy of
Charcot—a rare limb-threatening foot
deformity, characterized by presence of
pulsatile pedal arteries, development of
complex and diverse fractures, sublux-
ations, and reactive soft tissue swelling
after a minor and usually underestimated
trauma. The disease is triggered in sus-
ceptible individuals through a process
of uncontrolled inflammation leading
to osteolysis, progressive fractures and
articular malpositioning due to joint sub-
luxations and dislocations (Šponer et al.,
2013). Neuropathy and related local anes-
thesia predispose to chronic trauma of
the foot, while the autonomic neuropa-
thy results in increased regional blood
flow with resultant soft tissue edema and
local osteoporosis (Lechleitner et al., 2012;
Levitt et al., 2013).
In the acute phase, avoidance of weight
bearing is a prerequisite for prevention
of mid-foot collapse. Even after con-
solidation, abnormal bony prominences
may cause ulcerations and foot infections.
Surgical reconstruction is indicated if the
deformity can’t be adequately managed by
shoe modifications and bracing.
Generalized and local infections are
risk factors which may prevent recovery,
exclude favorable outcome, and increase
the rate of limb amputations in diabetic
foot patients (Wu et al., 2007; Levitt et al.,
2013; Šponer et al., 2013). Treatment is
started by the administration of wide
spectrum antibiotics covering both aer-
obic/anaerobic spectrum and continued
by specimen sensitive spectrum. Diabetic
ulcers are usually colonized by mixed
bacterial associations. Ischemic ulcers
frequently are colonized by anaerobes.
Preferred are IV Moxifloxacin or third
generation cephalosporine/metronidazole
combination. Antifungal treatment
is initiated immediately orally or IV.
Perioperative wound regeneration, graft
patency, and particularly affected limb
predetermination as well as postopera-
tive morbidity and mortality largely is
depending on effectiveness of antibacterial
prevention/treatment. A compromised
local and general immune response pre-
disposes to development of infections
per se, however, the risk increases signifi-
cantly in patients with underlying diabetic
polyneuropathy and chronic tissue
hypoxia/ischemia (Lipsky et al., 2012).
Approaches to surgical and pharmaco-
logical management of septic wounds are
well established. The therapy of infected
diabetic foot requires meticulous surgical
debridement and decompression of viable
tissues, mechanical, and pharmacological
destruction of the microbial biofilms in
combination with targeted systemic and
local antibacterial therapy. In addition to
the local therapeutic measures, systemic
correction of cardiovascular, respiratory,
renal, and blood coagulation functions is
mandatory (Frykberg et al., 2006; Zayed
et al., 2009; O’Reilly et al., 2011).
In conclusion, patients undergoing
surgery for diabetic foot are character-
ized with disorders of local and systemic
functions. The final surgical outcome
will depend on perioperative correc-
tion and stabilization of organ-systems,
tight control of blood glucose levels and
aggressive infection control.
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